FFM
ANAB icon

Fairmount Funds Management’s AnaptysBio ANAB Stock Holding History

Fairmount Funds Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,816,466
Closed -$24.1M – 16
2024
Q4 		$24.1M Buy
+1,816,466
New +$44M 2.39% 14

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fairmount Funds Management's ANAB Position: Q1 2025 in Review

Fairmount Funds Management sold out of AnaptysBio (ANAB) in Q1 2025, closing a stake of 1,816,466 shares — an estimated $24.1M sold.

Fairmount Funds Management first reported a position in ANAB in Q4 2024 and held it in 1 quarter. The position peaked at $24.1M in Q4 2024. 153 funds tracked by Wall St. Rank hold ANAB as of Q1 2025.

  • Fairmount Funds Management reported no remaining AnaptysBio position as of Q1 2025 after selling out during the quarter.
  • Fairmount Funds Management sold 1,816,466 AnaptysBio shares in Q1 2025, an estimated $24.1M.
  • Fairmount Funds Management first reported a position in AnaptysBio in Q4 2024 and held it in 1 quarter.
  • Fairmount Funds Management's AnaptysBio position peaked at $24.1M in Q4 2024.
  • 153 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2025.

Based on Fairmount Funds Management's 13F filing for Q1 2025, filed 15 May 2025.